Harpoon Therapeutics Inc. (NASDAQ:HARP) does about 2.29M shares in volume on a normal day but saw 277393 shares change hands in Friday trading. The company now has a market cap of 27.85M USD. Its current market price is $0.85, marking an increase of 1.44% compared to the previous close of $0.84. The 52 week high reached by this stock is $5.75 whilst the lowest price level in 52 weeks is $0.59. The script in recent trading has seen the stock touch a high of $0.8902 and a low of $0.82.
Harpoon Therapeutics Inc. (HARP) has a 20-day trading average at $1.0266 and the current price is -85.18% off the 52-week high compared with 45.48% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.8851 and its 200-day simple moving average is $1.4509. If we look at the stock’s price movements over the week, volatility stands at 16.02%, which decreases to 13.63% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 44.58 to suggest the stock is neutral.
The consensus objective for the share price is $6.81, suggesting that the stock has a potential upside of 87.52% over the period.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 6 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 06, 2022 when Canaccord Genuity resumed the stock to “Buy” and issued a price target of $16. Citigroup upgraded the stock to “Buy” from Neutral on September 28, 2021 at a price target of $16. Citigroup downgraded its price target at $25-$16.
The current price level is -17.04%, -3.38%, and -41.57% away from its SMA20, SMA50, and SMA200 respectively, with the HARP price moving above the 50-day SMA on February 17. Harpoon Therapeutics Inc. (HARP) stock is down -23.92% over the week and -0.93% over the past month. Its price is 17.42% year-to-date and -85.05% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.35 above consensus estimates by $0.21. The company’s next earnings report is expected on 05/11/2023, with forecasts estimating quarterly EPS at -$0.47 and -$1.99 for whole year. HARP’s earnings per share are forecast to grow by 45.00% this year and 53.80% over next year. Expected sales for next quarter are $4.05 million, which analysts say will come at $35.15 million for the current fiscal year and next year at $31.42 million. In addition, estimates put the company’s current quarterly revenue at an average of $7.04 million.
To reach the target analysts have set, the stock logically needs to grow 87.52 percent from here.
Outstanding shares total 33.06M with insiders holding 7.65% of the shares and institutional holders owning 71.14% of the company’s common stock. The company has a return on investment of -200.90% and return on equity of -198.20%. The beta has a value of 1.51. Price to book ratio is 1.67 and price to sales ratio is 0.86.
According to a U.S. Securities and Exchange Commission filing, Worldwide Healthcare Trust Plc has reduced its position in Harpoon Therapeutics Inc. (HARP) to 1,456,944 shares, mirroring a recent drop by -0.44%. Worldwide Healthcare Trust Plc dumped 6471.0 shares of Harpoon Therapeutics Inc. common stock bringing its total worth to about $1.57 million at the end of recent close, SEC documents show.
